Medication info

Imprida Tablet 5/160 mg

Prescription medicationApproval withdrawn
Ingredient · strength
Valsartan›Strength being verifiedAmlodipine Besylate›Strength being verified
Manufacturer / importer
SANDOZ KOREA
Appearance
Dark yellow oval film-coated tablet
Packaging
28 tablets (14 tablets/PTP packaging X2), 28 tablets (7 tablets/PTP packaging X4)
Approval status
Approval withdrawn

MFDS item code 201305048 · Approved 2013.02.15

This product's status changed to Approval withdrawn on 2023.06.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who uses it
Adults · Children
Adult dosage
The recommended dose of this medication is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before starting this medication, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medication may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment (creatinine clearance at least 10mL/min). However, this medication should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients undergoing dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. This medication should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Patients aged 65 years and older: Use caution when increasing the dose.
Children's dosage
The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Ingredients

Importer
SANDOZ KOREA

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medicine is used for patients with essential hypertension who do not have adequate blood pressure control with monotherapy of amlodipine or valsartan.

Dosage and Administration

Adult dosage

The recommended dose of this medication is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before starting this medication, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medication may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment (creatinine clearance at least 10mL/min). However, this medication should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients undergoing dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. This medication should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Patients aged 65 years and older: Use caution when increasing the dose.

Children's dosage

The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Precautions

This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication's active ingredients or similar class medications, women who are pregnant or breastfeeding, and patients with severe kidney or liver dysfunction should not take this drug. Patients who are depleted of sodium or fluids may experience hypotension, so their condition should be evaluated carefully before taking the medication, and blood pressure and condition monitored closely during treatment. Patients with high potassium levels or those taking potassium supplements need regular monitoring of potassium levels, and caution is needed for patients with vascular issues in the kidneys. Caution is also advised for patients with cardiac conditions, such as heart failure or after myocardial infarction, and patients with aortic stenosis. If symptoms of angioedema occur, the medication should be stopped immediately and not resumed. Caution is required when driving or operating machinery due to potential dizziness or fatigue. This medication may increase the risk of hypotension, hyperkalemia, or renal impairment when used in combination with other antihypertensives, so blood pressure and renal function should be closely monitored when used together. Women who are pregnant or planning pregnancy should not take this medication, and its use is not recommended in nursing mothers. Safety and efficacy have not been sufficiently established in pediatric patients, so its use is discouraged. In the event of overdose, hypotension or serious side effects may occur, so dosage must be strictly adhered to, and medical attention sought immediately if unusual symptoms appear.

Side effects

nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, dizziness, drowsiness, positional dizziness, sensory disturbance, vertigo, tinnitus, tachycardia, palpitations, syncope, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, xerostomia, rash, erythema, hyperhidrosis, itching, joint swelling, low back pain, arthritis, muscle spasms, lethargy, polyuria, nocturia, erectile dysfunction, edema, regional edema, facial edema, peripheral edema, fatigue, flushing, asthenia, facial flushing, decreased hemoglobin, decreased hematocrit, neutropenia, thrombocytopenia, hypersensitivity including serum sickness, increased serum potassium, vasculitis, elevated liver function tests, angioedema, vesicular dermatitis, myalgia, renal failure, kidney damage, increased serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral infection, diplopia, thrombocytopenia, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremors, sensory loss, taste disorder, peripheral neuropathy, hypertonicity, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, myocardial infarction, vasculitis, dyspnea, rhinitis, vomiting, dyspepsia, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity reaction, angioedema, urticaria, erythema multiforme, Stevens-Johnson syndrome, myalgia, dysuria, nocturnal enuresis, gynecomastia, pain, malaise, chest pain, weight loss, weight gain, increased liver enzymes, chest discomfort, abdominal discomfort, gastroesophageal reflux disease, neck pain, hypercholesterolemia, hypoglycemia, nervousness, Stevens-Johnson syndrome, chest pain, weight gain, arthralgia, musculoskeletal pain, rhabdomyolysis, gingival hyperplasia, gastritis, sensory loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is safe to store it at room temperature between 1 degree and 30 degrees Celsius. This storage condition helps maintain the efficacy of the medication and prevent deterioration.

Appearance and packaging

Appearance

Dark yellow oval film-coated tablet

Package unit

28 tablets (14 tablets/PTP packaging X2), 28 tablets (7 tablets/PTP packaging X4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.